Trump Strikes Again: Sends Warning Letter to Eli Lilly and Others, Drug Pricing Back in the Spotlight

Source Tradingkey

TradingKey - On Thursday Eastern Time, U.S. President Donald Trump renewed pressure on the pharmaceutical industry by sending formal letters to several major drugmakers—including Eli Lilly (LLY.US), GlaxoSmithKline (GSK.US), Johnson & Johnson, Regeneron Pharmaceuticals (REGN.US), and AstraZeneca (AZN.US)—demanding concrete action on drug pricing within 60 days. The administration warned that if no progress is made, it will “activate appropriate tools to protect the interests of American citizens.”

The news triggered sharp selloffs across the sector:

  • Eli Lilly (LLY.US) reversed earlier gains, closing down more than 2.15%.
  • GlaxoSmithKline (GSK.US) plunged over 4%.
  • AstraZeneca (AZN.US) declined nearly 4%.
  • Johnson & Johnson (JNJ.US) and Regeneron (REGN.US) both fell more than 1%.
  • Novo Nordisk (NVO.US), already under pressure, dropped another 5%.

The move is widely seen as a signal of Trump’s intent to follow through on his campaign pledge to tackle high drug prices in a potential second term. Drug pricing has long been a politically charged issue and a top concern for American voters. While the letter stopped short of detailing specific measures, market participants anticipate potential steps such as:

  • Expanding government price negotiation authority,
  • Allowing more aggressive use of imported drug alternatives,
  • And launching hearings and investigations into high-profit drug products.

For investors, the message is clear: regulatory scrutiny remains a significant overhang. Even with enthusiasm around AI and biotech innovation, legacy pharmaceutical firms are still squarely in the regulatory crosshairs. In the near term, large-cap drugmakers could see valuation pressure, while smaller, innovative pharmaceutical companies may face heightened risk around pricing power and reimbursement for their products.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
South Korea’s KOSPI Tumbles Nearly 4% as Tax Hike Plans and US Tariffs LoomSouth Korea's KOSPI index dropped over 3% at Friday's opening, marking the biggest decline since early April.
Author  TradingKey
8 hours ago
South Korea's KOSPI index dropped over 3% at Friday's opening, marking the biggest decline since early April.
placeholder
Forex Today: July Nonfarm Payrolls data to keep volatility high heading into weekendMarkets turn quiet early Friday as investors assess the latest headlines surrounding the United States' (US) trade regime, while gearing up for the July employment report.
Author  FXStreet
8 hours ago
Markets turn quiet early Friday as investors assess the latest headlines surrounding the United States' (US) trade regime, while gearing up for the July employment report.
placeholder
Solana, Dogecoin, and Cardano lead decline amid $635 million crypto market liquidationsThe cryptocurrency market is down on Friday, underpinned by the US Federal Reserve's decision to keep interest rates stable at 4.25% to 4.50% for the fifth consecutive time.
Author  FXStreet
9 hours ago
The cryptocurrency market is down on Friday, underpinned by the US Federal Reserve's decision to keep interest rates stable at 4.25% to 4.50% for the fifth consecutive time.
placeholder
Nonfarm Payrolls set to show hiring moderated in July as US labor market coolsUnited States Nonfarm Payrolls (NFP) data for July will be published by the Bureau of Labor Statistics (BLS) on Friday at 12:30 GMT.
Author  FXStreet
10 hours ago
United States Nonfarm Payrolls (NFP) data for July will be published by the Bureau of Labor Statistics (BLS) on Friday at 12:30 GMT.
placeholder
Gold price flat lines above one-month low as traders seem reluctant ahead of US NFP reportGold price (XAU/USD) trades with a negative bias below the $3,300 mark during the Asian session on Friday.
Author  FXStreet
10 hours ago
Gold price (XAU/USD) trades with a negative bias below the $3,300 mark during the Asian session on Friday.
goTop
quote